Official operations of Otsuka (Philippines) Pharmaceutical, Inc. (OPPI) began January, 1998 with sixty-five employees, composed mainly of medical representatives deployed nationwide promoting Otsuka products namely Meptin (Procaterol), a bronchodilator; Mikelan (Carteolol), a beta-blocker; Aminoleban Injection and Aminoleban EN (Amino acids)
for the treatment of hepatic encephalopathy and Nutritional supplement for liver failure patients; and Pletaal (Cilostazol) an antiplatelet agent.

Over the years of its incorporation, OPPI continues to grow despite many economic and political issues. In 2003, OPPI launched Mucosta (Rebamipide), a cytoprotective agent indicated for the treatment of gastritis and gastric ulcer. The following year, to address the concerns of many patients taking Aminoleban EN, Aminoleban ORAL was launched. Aminoleban Oral offers the same nutritional value as the Aminoleban EN, more affordable with palatable taste amino acid enteral solution.

In October 2005, OPPI launched its blockbuster antipsychotic drug Abilify (Aripiprazole). August 2006 marked the entry of Firebird, a drug eluting stent.

OPPI is continuously growing and in 2007 it will enter the consumer market with its isotonic drink Pocari Sweat.

What started as a small division of Marsman & Drug, Inc. in 1985 to its establishment as Otsuka (Philippines) Pharmaceutical, Inc. in 1997, Otsuka Philippines proves that it can face the challenges in the pharmaceutical market, thus 2006 marked the Otsuka Rising!